Cargando…

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?

Detalles Bibliográficos
Autores principales:	Wang, Luxiang, Zhang, Chunli, Fan, Shuang, Mo, Xiaodong, Hu, Xiaoxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10336665/ https://www.ncbi.nlm.nih.gov/pubmed/37448742 http://dx.doi.org/10.1016/j.xinn.2023.100461

Ejemplares similares

In-depth time-dependent analysis of the benefit of allo-HSCT for elderly patients with CR1 AML: a FILO study
por: Devillier, Raynier, et al.
Publicado: (2022)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2020)

PB2407: ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT) WITH CYCLOPHOSPHAMIDE IN PEDIATRIC HIGH-RISK ACUTE MYELOID LEUKEMIA (HR-AML)
por: Sun, Ming, et al.
Publicado: (2023)

Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2021)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Treatment of AML Relapse After Allo-HCT
por: Webster, Jonathan A., et al.
Publicado: (2021)

GARP-mediated active TGF-β1 induces bone marrow NK cell dysfunction in AML patients with early relapse post–allo-HSCT
por: Wang, Dongyao, et al.
Publicado: (2022)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

TKIs combined with chemotherapy followed by allo-HSCT in Philadelphia chromosome-positive myelodysplastic syndrome: A case report and literature review
por: Qi, Shasha, et al.
Publicado: (2022)

P570: VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

Allo-parapatric speciation goes offshore
por: Price, Trevor
Publicado: (2019)

Preemptive interferon-α treatment could protect against relapse and improve long-term survival of ALL patients after allo-HSCT
por: Liu, Sining, et al.
Publicado: (2020)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

P390: ALLO-HSCT OR CHEMOTHERAPY FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA IN THE FIRST COMPLETE REMISSION: IMPACT OF MRD AND IKZF1
por: Deng, Shiyu, et al.
Publicado: (2023)

Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt’s lymphoma: a case report
por: Cheng, Ling, et al.
Publicado: (2022)

A Nationwide Study of GATA2 Deficiency in Norway—the Majority of Patients Have Undergone Allo-HSCT
por: Jørgensen, Silje F., et al.
Publicado: (2021)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
por: Cerezo-Martin, J. M., et al.
Publicado: (2022)

Clinical study of late-onset hemorrhagic cystitis after allo-HSCT without in vitro T-cell depletion
por: Yuan, Hailong, et al.
Publicado: (2022)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis
por: Yang, Apeng, et al.
Publicado: (2019)

Pre-transplant Rehabilitation to Decrease the Post-transplant Length of Stay for Hematological Malignancy Patients Undergoing Allo-HSCT
por: Matsugaki, Ryutaro, et al.
Publicado: (2021)

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
por: Ren, Jinhua, et al.
Publicado: (2023)

PD-1 and CTLA-4 up regulation on donor T cells is insufficient to prevent GvHD in allo-HSCT recipients
por: Hossain, Mohammad S., et al.
Publicado: (2017)

Re-discovering NK cell allo-reactivity in the therapy of solid tumors
por: Castagna, Luca, et al.
Publicado: (2016)

Intestinal Microbiota at Engraftment Influence Acute Graft-Versus-Host Disease via the Treg/Th17 Balance in Allo-HSCT Recipients
por: Han, Lijie, et al.
Publicado: (2018)

Myeloma as a Second Malignancy following AML: Is a Second Allo Equivalent to Auto?
por: Bakanay, Sule Mine, et al.
Publicado: (2012)

Fulminant isolated adenovirus hepatitis 5 months after haplo-identical HSCT for AML
por: Detrait, Marie, et al.
Publicado: (2015)

Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Spain (GETH-MIC)
por: López-Sánchez, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_306ahl3qq7ros4a5vf4lbu0gl1